Is AbbVie (ABBV) overvalued or fairly valued?

MarketChacha shows AbbVie's valuation in context — a forward P/E of about 15.6 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is the share price of AbbVie (ABBV)?

AbbVie last traded at $253.38 (-0.4% on the day), as of 7/20/2026 — a delayed quote shown for education, not investment advice.

AbbVie

ABBV · NYSE · Pharma · United States

$253.38-0.4%

Delayed · as reported by Yahoo Finance · as of Jul 20, 2026, 8:02 PM

Snapshot

TickerABBV

ExchangeNYSE

SectorPharma

IndustryDrug Manufacturers - General

CountryUnited States

Employees57,000

HeadquartersNorth Chicago, United States

Market cap$447.7B

Volume4.33M

Websitewww.abbvie.com

Filings tracked0

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Profile as reported by Yahoo Finance.

Who owns it

Insiders0.1%
Institutions76.9%
Public & other23.0%

5,107 institutional holders

As reported by Yahoo Finance.

Top holders

Blackrock Inc.8.53%
Vanguard Capital Management LLC6.50%
State Street Corporation4.60%
JPMORGAN CHASE & CO3.21%
Vanguard Portfolio Management LLC2.80%
Geode Capital Management, LLC2.65%
Morgan Stanley2.15%
Capital Research Global Investors1.77%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

What's expected next

Next quarter

Rev $17.3B · EPS 3.84

Est. earnings growth +106.3%

Next fiscal year

Rev $72.8B · EPS 16.28

Est. earnings growth +15.1%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$184.6352-wk range$261.64

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Ask MarketChacha about ABBV

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.